Venrock Overview

  • Investor Type
  • Venture Capital

  • Status
  • Active

  • Professionals
  • 25


  • Investments
  • 1,005

  • Portfolio
  • 116

  • Exits
  • 470


Venrock General Information


Founded in 1969, Venrock is a Venture Capital arm of Rockefeller Group Investment Management based in Palo Alto, California. The firm has additional offices in Boston and New York. The firm seeks to invest in companies operating in the technology, healthcare, consumer, cryptocurrency, cybersecurity, defense & aerospace, security & infrastructure, financial technology, software-as-a-service, and artificial intelligence sectors based in the United States.

Contact Information

Formerly Known As
Venrock Associates
Year Founded
Investor Status
Actively Seeking New Investments
Trade Association
New England Venture Capital Association (NEVCA)
National Venture Capital Association (NVCA)
Primary Investor Type
Venture Capital
Other Investor Types
Primary Office
  • 3340 Hillview Avenue
  • Silicon Valley
  • Palo Alto, CA 94304
  • United States
+1 (650) 000-0000

Venrock Investments & Acquisitions (1,005)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
MBrace Therapeutics 21-Nov-2023 Early Stage VC 0000 Drug Discovery Pre-Clinical Trials 0000000 0000000
Viridian Therapeutics 01-Nov-2023 0000 00000 Biotechnology Generating Revenue/Not Profitable
Scope3 19-Sep-2023 00000 00000 0000 Media and Information Services (B2B) Generating Revenue 0000000 0000000
Dianthus Therapeutics 11-Sep-2023 0000 0000 Drug Discovery Generating Revenue/Not Profitable
Moment (Financial Software) 06-Sep-2023 0000 00000 0000 Financial Software Generating Revenue
Taysha Gene Therapies 16-Aug-2023 0000 00000 Drug Discovery Generating Revenue/Not Profitable
ADARx Pharmaceuticals 02-Aug-2023 00000 00000 00000 Biotechnology Clinical Trials - Phase 1
Tisento Therapeutics 01-Aug-2023 00000 00000 0000 Biotechnology Clinical Trials - Phase 2
Upstream Bio 06-Jul-2023 Early Stage VC 00000 Biotechnology Clinical Trials - General 0000 00000 00
Candid (Therapeutic Devices) 29-Jun-2023 Later Stage VC 000 Therapeutic Devices Generating Revenue
You’re viewing 10 of 1,005 investments and acquisitions. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Venrock Exits (470)

Company Name Exit Date Exit Type Exit Size
Sitka 14-Nov-2023 Merger/Acquisition
RayzeBio 15-Sep-2023 000 00000
Dianthus Therapeutics 11-Sep-2023 0000000 000000 00000
Socrates.Ai 15-Aug-2023 000000000000000000
Apogee Therapeutics 13-Jul-2023 000 00000
Lusaris Therapeutics 30-May-2023 000 00 00000000
Qteros 01-Mar-2023 000000000 00000000
Replicor 01-Feb-2023 000000000 00000000
Burner 01-Dec-2022 Secondary Transaction - Private
Market Realist 01-Nov-2022 Merger/Acquisition
You’re viewing 10 of 470 exits. Get the full list »

Venrock Fund Performance

Fund Name Vintage Size Dry Powder DPI RVPI TVPI IRR

This information is available in the PitchBook Platform. To explore Venrock‘s full profile, request access.

Request a free trial

Venrock Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Venrock Team (87)

Name Title Deals Funds Boards Office
Lisa Harris Chief Financial Officer & Finance Partner Palo Alto, CA
Evan Neu Partner, Chief Compliance Officer & General Counsel Palo Alto, CA
Nicole Pack Chief Marketing Officer & Marketing Partner Palo Alto, CA
Brian Ascher Partner 00 0 0 Palo Alto, CA
Camille Samuels Partner 00 00 0 Palo Alto, CA
You’re viewing 5 of 87 team members. Get the full list »

Venrock Co-Investors (647)

Name With Exits Lead Partner Series Industry
Logos Capital 14 0 0 Series chart Industry bar
RA Capital Management 00 0 00 Series chart Industry bar
Fidelity Management & Research 00 0 0 Series chart Industry bar
Janus Henderson Investors 00 0 0 Series chart Industry bar
OrbiMed 00 0 0 Series chart Industry bar
You’re viewing 5 of 647 co-investors. Get the full list »